Technical Analysis for IXHL - Incannex Healthcare Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | -10.07% | |
| 200 DMA Support | Bullish | -10.07% | |
| Upper Bollinger Band Walk | Strength | -10.07% |
| Alert | Time |
|---|---|
| Gap Up Closed | 1 day ago |
| Gap Up Partially Closed | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below 200 DMA | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 02/26/2024
Incannex Healthcare Limited Description
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Organ Systems Drugs Neuroscience Chemical Compounds Rheumatoid Arthritis Asthma Inflammatory Bowel Disease Respiratory Therapy Chronic Obstructive Pulmonary Disease Sleep Apnea Sleep Disorders Obstructive Sleep Apnea Cannabidiol Cannabinoid Acute Respiratory Distress Syndrome Traumatic Brain Injury
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.68 |
| 52 Week Low | 0.8 |
| Average Volume | 64,133 |
| 200-Day Moving Average | 2.73 |
| 50-Day Moving Average | 2.91 |
| 20-Day Moving Average | 2.53 |
| 10-Day Moving Average | 2.61 |
| Average True Range | 0.30 |
| RSI (14) | 45.05 |
| ADX | 14.77 |
| +DI | 27.25 |
| -DI | 23.93 |
| Chandelier Exit (Long, 3 ATRs) | 2.36 |
| Chandelier Exit (Short, 3 ATRs) | 3.02 |
| Upper Bollinger Bands | 2.98 |
| Lower Bollinger Band | 2.07 |
| Percent B (%b) | 0.47 |
| BandWidth | 36.28 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.12 |
| MACD Histogram | 0.0631 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.20 | ||||
| Resistance 3 (R3) | 3.26 | 3.09 | 3.08 | ||
| Resistance 2 (R2) | 3.09 | 2.91 | 3.06 | 3.04 | |
| Resistance 1 (R1) | 2.79 | 2.80 | 2.71 | 2.73 | 3.00 |
| Pivot Point | 2.62 | 2.62 | 2.58 | 2.59 | 2.62 |
| Support 1 (S1) | 2.33 | 2.44 | 2.24 | 2.27 | 2.00 |
| Support 2 (S2) | 2.16 | 2.33 | 2.13 | 1.96 | |
| Support 3 (S3) | 1.86 | 2.16 | 1.92 | ||
| Support 4 (S4) | 1.80 |
